DARAPRIM (KAISER FOUNDATION HOSPITALS)


Welcome to the PulseAid listing for the DARAPRIM drug offered from KAISER FOUNDATION HOSPITALS. This Dihydrofolate Reductase Inhibitor Antimalarial [EPC],Dihydrofolate Reductase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: KAISER FOUNDATION HOSPITALS
NON-PROPRIETARY NAME: pyrimethamine
SUBSTANCE NAME: PYRIMETHAMINE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Dihydrofolate Reductase Inhibitor Antimalarial [EPC],Dihydrofolate Reductase Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2011-04-20
END MARKETING DATE: 0000-00-00


DARAPRIM HUMAN PRESCRIPTION DRUG Details:

Item DescriptionDARAPRIM from KAISER FOUNDATION HOSPITALS
LABELER NAME: KAISER FOUNDATION HOSPITALS
DEA SCHEDULE:
ACTIVE STRENGTH: 25(mg/1)
START MARKETING DATE: 2011-04-20
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0179-0090_f481691b-d760-420e-a1df-e1c6ff084cb4
PRODUCT NDC: 0179-0090
APPLICATION NUMBER: NDA008578

Other PYRIMETHAMINE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Amedra Pharmaceuticals LLCDARAPRIM
KAISER FOUNDATION HOSPITALSDARAPRIM
Vyera Pharmaceuticals LLCDaraprim